Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2003-10-27
2009-10-06
Aeder, Sean E (Department: 1642)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
Reexamination Certificate
active
07598229
ABSTRACT:
The invention relates to prophylactic and therapeutic vaccines for protecting individuals against metastatic colorectal cancer and for treating individuals who are suffering from metastatic colorectal cancer.
REFERENCES:
patent: 4022878 (1977-05-01), Gross
patent: 4329281 (1982-05-01), Christenson et al.
patent: 4526716 (1985-07-01), Stevens
patent: 4736866 (1988-04-01), Leder et al.
patent: 4873191 (1989-10-01), Wagner et al.
patent: 4945050 (1990-07-01), Sanford et al.
patent: 5017487 (1991-05-01), Stunnenberg et al.
patent: 5037645 (1991-08-01), Strahilevitz
patent: 5112606 (1992-05-01), Shiosaka et al.
patent: 5237051 (1993-08-01), Garbers et al.
patent: 5273745 (1993-12-01), Schirrmacher
patent: 5352775 (1994-10-01), Albertsen et al.
patent: 5484596 (1996-01-01), Hanna et al.
patent: 5518888 (1996-05-01), Waldman
patent: 5601990 (1997-02-01), Waldman
patent: 5731159 (1998-03-01), Waldman et al.
patent: 5879656 (1999-03-01), Waldman et al.
patent: WO 90/11092 (1990-10-01), None
patent: WO 95/11694 (1995-05-01), None
Roitt et al (Immunology, 1993, 3rd ed, Mosby, London).
Holmes (Exp. Opin. Invest. Drugs, 2001, 10(3):511-519).
Crystal, R.G. (Science, vol. 270, Oct. 1995, pp. 404-410).
Tait et al. (Clin.Canc.Res., vol. 5, Jul. 1999, pp. 1708-1714).
Gura (Science, 1997, 278:1041-1042.).
Almenoff et al (Journal of Biological Chemistry, 1994, 24(17): 16610-16617).
Almenoff et al (journal of Biological Chemistry, Jun. 17, 1994, 269(24):16610-16617).
Verma et al. (Nature 1997, 389: 239-242).
Amalfitano et al. (Current Gene Therapy 2002, 2: 111-133).
Almenoff et al., “Induction of heat-stable enterotoxin receptor activity by a human Alu repeat,”J. Biol. Chem., 1994, 269(24), 16610-16617.
Berd et al., “Immunization with Haptenized, Autologous Tumor Cells Induces Inflammation of Human Melanoma Metastases”,Cancer Res., 1991, 51, 2731-2734.
Berd et al., “Induction of Cell-mediated Immunity to Autologous Melanoma Cells and Regression of Metastases after Treatment with a Melanoma Cell Vaccine Preceded by Cyclophosphamide”,Cancer Res., 1986, 46, 2572-2577.
Carrithers et al., “Escherichia coliheat-stable toxin receptors in human colonic tumors,”Gastroenterology, 1994, 107, 1653-1661.
Carrithers et al., “Escherichia coliheat-stable enterotoxin receptors. A novel marker for colorectal tumors,”Diseases Colon&Rectum, 1996, 39(2), 171-181.
Francis et al., Peptide Vaccines Based on Enhanced Immunogenicity of Peptide Epitopes Presented with T-Cell Determinants or Hepatitis B Core Protein,Methods in Enzymol., 1989, 178, 659-676.
MacLean et al., “Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant”,Cancer Immunol. Immunother., 1993, 36, 215-222.
Miller et al., “The Induction of Hapten-Specific T Cell Tolerance by Using Hapten-Modified Lymphoid Cells”,J. Immunol., 1976, 117(5:1), 1519-1526.
Rudner et al., “Regulation of cell signaling by the cytoplasmic domains of the healt-stable enterotoxin receptor: Identification of autoinhibitory and activating motifs”,Proc. Natl. Acad. Sci., 1995, 92, 5169-5173.
Sad et al., “Bypass of carrier-induced epitope-specific suppression using a T-helper epitope”,Immunology, 1992, 76, 599-603.
Waldman et al., “Immunoaffinity Purification of Soluble Guanylyl Cyclase”,Methods Enzymol., 1991, 195, 391-396.
Banchereau et al., “Immune and clinical responses in patient with metastatic melanoma to CD34+ progenitor-derived dendritic cell vaccine,”Cancer Research(2001) 61:6451-6458.
Bellone et al., “Cancer immunotherapy: synthetic and natural peptides in the balance,”Immunology Today(1999) 20(10):457-462.
Carrithers et al., “Escherichia coliheat-stable toxin receptors in human colonic tumors,”Gastroenterology(1994) 107:1653-1661.
Celis et al., “Identification of potential CTL epitopes of tumor-associated antigen MAGE-1 for five common HLA-A alleles,”Molecular Immunology(1994) 31(18):1423-1430.
Disis et al., “Peptide-based, but not whole protein, vaccines elicit immunity to HER-2
eu, oncogenic self-protein,”J. of Immunology(1996) 156:3151-3158.
Foon et al., “Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen,”Journal of Clinical Oncology(1999) 17(9):2889-2895.
Herbert et al.,The Dictionary of Immunology, Academic Press, 4thed. (1995).
Greenspan et al., “Defining epitopes: It's not as easy as it seems,”Nature Biotechnology(1999) 7:936-937.
Gura “Systems for identifying new drugs are often faulty,”Science(1997) 278:1041-1042.
Mallo et al., “Expression of theCdx1andCdx2homeotic genes leads to reduced malignancy in colon cancer-derived cells,”J. Biological Chemistry(1998) 273(22):14030-14036.
Nelson et al.,J. Nat'l. Can. Ins. (1996) 88(8):468-488.
Reynolds et al., “Vaccine-induced CD8+ T-cell responses to MAGE-3 correlate with clinical outcome in patients with melanoma,”Clinical Cancer Research(2003)9:657-662.
Singh et al., “Isolation and expression of a guanylate cyclase-coupled heat stable enterotoxin receptor cDNA from a human colonic cell line,”Biochem. Biophy. Res. Comm. (1991) 179(3):1455-1463.
Smith “Cancer and the immune system,”Pediatr Clin North Am. (1994) 41(4) 841-850.
Spitler “Cancer vaccines: the interferon analogy,”Cancer Biotherapy(1995) 10:1-3.
Welzien HU “Renaissance for hapten-specific T lymphocytes: implications for basic and applied research,”Z Naturforsch[C] (1992) 47(5-6):323-328.
Miller et al., “Improved survival of patients with Melanoma with an antibody response to immunization of a polyvalent melanoma vaccine,”Cancer(1995) 75(2):495-502.
Aeder Sean E
Pepper Hmailton LLP
Thomas Jefferson University
LandOfFree
Metastatic colorectal cancer vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Metastatic colorectal cancer vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Metastatic colorectal cancer vaccine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4087627